ExagenXGN
XGN
About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Employees: 209
0
Funds holding %
of 7,327 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.19% more ownership
Funds ownership: 34.65% [Q4 2024] → 34.84% (+0.19%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
7% less funds holding
Funds holding: 41 [Q4 2024] → 38 (-3) [Q1 2025]
11% less capital invested
Capital invested by funds: $25.1M [Q4 2024] → $22.4M (-$2.66M) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
73% less call options, than puts
Call options by funds: $18K | Put options by funds: $66K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
19%
downside
Avg. target
$11.75
36%
upside
High target
$17
97%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Kyle Mikson | 27%upside $11 | Buy Maintained | 30 Jul 2025 |
Keybanc Paul Knight | 97%upside $17 | Overweight Upgraded | 30 Jul 2025 |
Craig-Hallum John Wilkin | 39%upside $12 | Buy Initiated | 23 Jul 2025 |
Cantor Fitzgerald Ross Osborn | 19%downside $7 | Overweight Maintained | 15 May 2025 |
Financial journalist opinion
Based on 7 articles about XGN published over the past 30 days
Neutral
Seeking Alpha
3 days ago
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Margarate Elizabeth Boeye - William Blair & Company L.L.C.
Neutral
The Motley Fool
3 days ago
Exagen Q2 Revenue Jumps 14 Percent
Exagen Q2 Revenue Jumps 14 Percent
Positive
Zacks Investment Research
3 days ago
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Neutral
GlobeNewsWire
3 days ago
Exagen Inc. Reports Strong Q2 2025 Results
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates.
Positive
Zacks Investment Research
1 week ago
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
2 weeks ago
Exagen Inc. Appoints Chas McKhann to Board of Directors
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT).
Neutral
GlobeNewsWire
1 month ago
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer.
Neutral
GlobeNewsWire
2 months ago
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025.
Neutral
GlobeNewsWire
2 months ago
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.
Charts implemented using Lightweight Charts™